Statement: no diarrhea was identified among the patients of the secondary trial, whereas multiple instances were detected among the participants of the primary trial
Primary_evidence: Adverse Events 1:   Total: 59/373 (15.82%)   Neutropenia 14/373 (3.75%)   Febrile neutropenia 10/373 (2.68%)   Leukopenia 1/373 (0.27%)   Anaemia 2/373 (0.54%)   Lymphadenopathy 0/373 (0.00%)   cardiac failure 2/373 (0.54%)   Atrial fibrillation 1/373 (0.27%)   Pericardial effusion 2/373 (0.54%)   Cardiac failure congestive 1/373 (0.27%)   Cardiomyopathy 0/373 (0.00%) Adverse Events 2:   Total: 69/377 (18.30%)   Neutropenia 17/377 (4.51%)   Febrile neutropenia 10/377 (2.65%)   Leukopenia 4/377 (1.06%)   Anaemia 2/377 (0.53%)   Lymphadenopathy 1/377 (0.27%)   cardiac failure 1/377 (0.27%)   Atrial fibrillation 1/377 (0.27%)   Pericardial effusion 0/377 (0.00%)   Cardiac failure congestive 0/377 (0.00%)   Cardiomyopathy 1/377 (0.27%)
Secondary_evidence: Adverse Events 1:   Total: 0/92 (0.00%)   Diarrhea 0/92 (0.00%) Adverse Events 2:   Total: 1/93 (1.08%)   Diarrhea 1/93 (1.08%)